SCHEMBL1336033

SCHEMBL1336033

Cc1cc(COC(=O)Nc2ccccc2)cc(C)n1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.60
MGLL Q99685 2/20 0.57
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MAPT P10636 2/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ENPP2 Q13822 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
ROCK2 O75116 1/20 0.50
RECQL P46063 1/20 0.50
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334854 0.83 POLB (0.61) POLBMGLLNPC1RAB9ALMNA
SCHEMBL10595799 0.82 POLB (0.73) POLBMGLLNPC1RAB9ALMNA
Benzyl Phenylcarbamate SCHEMBL1222943 0.82 POLB (0.78) POLBMGLLNPC1RAB9ALMNA
SCHEMBL10076576 0.81 MEN1 (0.70) POLBMGLLNPC1RAB9ALMNA
SCHEMBL12126865 0.79 MEN1 (0.42) POLBMGLLNPC1RAB9ASMN1; SMN2
SCHEMBL1334862 0.78 POLB (0.88) POLBMGLLNPC1RAB9ALMNA
SCHEMBL5852207 0.78 POLB (0.68) POLBMGLLNPC1RAB9ASMN1; SMN2
SCHEMBL11787221 0.78 POLB (0.52) POLBMGLLNPC1RAB9ALMNA
SCHEMBL5853166 0.78 MGLL (0.72) POLBMGLLNPC1RAB9ALMNA
Benzyl Phenylcarbamate SCHEMBL2635177 0.78 POLB (0.71) POLBMGLLNPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US claimed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP claimed
WO-2009147216-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS BIOVITRUM AB (PUBL) (SE) 2009-12-10 WO claimed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP disclosed
WO-2009147216-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS BIOVITRUM AB (PUBL) (SE) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics GPR119, GLP1R, ADIPOR1 POLB 4125/4885MGLL 654/4885NPC1 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.